Ellis Pharmaceuticals, LLC cash flow statements are as follows:

Description	2019	2018	2017	2016
Beginning Cash	511	452	103	100
Cash from Operating	-58	-115	-205	-415
Cash from Investing	-179	105	116	203
Cash from Financing	-216	69	438	215
Net Change in Cash	-453	59	349	3
Ending Cash	58	511	452	103

Choose one assertion we cannot make from this data:

	A.	The cash drain has ended.
	B.	Ellis has been selling assets until 2019.
	C.	Ellis either borrowed money or sold equity in 2017.
	D.	Ellis most likely repaid debt in 2019.